Deborah L. Toppmeyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Deborah L. Toppmeyer has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Michelle Orlick
UMDNJ‐Robert Wood Johnson Medical School, Cancer Institute of New Jersey, New Brunswick, New Jersey
1 shared publicationNicola Barnard
Departments of Medicine and
1 shared publicationSerena T. Wong
The Cancer Institute of New Jersey
1 shared publicationSusan Goodin
1 shared publicationSusan Lindrud
UMDNJ-Robert Wood Johnson Medical School, Cancer Institute of New Jersey, New Brunswick 08901, USA
1 shared publicationWilliam N. Hait
UMDNJ‐Robert Wood Johnson Medical School, Cancer Institute of New Jersey, New Brunswick, New Jersey
1 shared publication
Latest Publications
- 1 October 2010
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 33 (5) , 516-521
Ixabepilone, a New Treatment Option for Metastatic Breast Cancer
Patients with metastatic breast cancer (MBC) who develop resistance to anthracyclines and taxanes have limited therapeutic options. There is an unmet need for agents that can overcome tumor resistance and are effective in treating drug-resistant disease. The novel epothilone B analog, ixabepilone, binds to β-tubulin and stabilizes microtubules, leading to growth inhibition and apoptosis. Ixabepilone is able to overcome common mechanisms of resistance that limit the efficacy of many chemotherapeutic agents such as anthracyclines, taxanes, and capecitabine. Single-agent ixabepilone has clinical activity and a manageable safety profile against several different solid tumors including MBC, nonsmall cell lung cancer (NSCLC), and prostate cancer. Several phase II and III trials have demonstrated that ixabepilone-as monotherapy and in combination with capecitabine-is active in patients with pretreated or resistant MBC. Ixabepilone is the first epothilone approved for use as monotherapy or in combination with capecitabine in the treatment of metastatic or locally advanced breast cancer that is resistant or refractory to anthracyclines, taxanes, and/or capecitabine. Further clinical studies are evaluating the combination of ixabepilone with targeted agents such as trastuzumab or bevacizumab to further define the role of this novel agent in the treatment of MBC.
- 1 October 2010
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 33 (5) , 516-521
Ixabepilone, a New Treatment Option for Metastatic Breast Cancer
Patients with metastatic breast cancer (MBC) who develop resistance to anthracyclines and taxanes have limited therapeutic options. There is an unmet need for agents that can overcome tumor resistance and are effective in treating drug-resistant disease. The novel epothilone B analog, ixabepilone, binds to β-tubulin and stabilizes microtubules, leading to growth inhibition and apoptosis. Ixabepilone is able to overcome common mechanisms of resistance that limit the efficacy of many chemotherapeutic agents such as anthracyclines, taxanes, and capecitabine. Single-agent ixabepilone has clinical activity and a manageable safety profile against several different solid tumors including MBC, nonsmall cell lung cancer (NSCLC), and prostate cancer. Several phase II and III trials have demonstrated that ixabepilone-as monotherapy and in combination with capecitabine-is active in patients with pretreated or resistant MBC. Ixabepilone is the first epothilone approved for use as monotherapy or in combination with capecitabine in the treatment of metastatic or locally advanced breast cancer that is resistant or refractory to anthracyclines, taxanes, and/or capecitabine. Further clinical studies are evaluating the combination of ixabepilone with targeted agents such as trastuzumab or bevacizumab to further define the role of this novel agent in the treatment of MBC.
- 25 February 2010
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 2 (1) , 16-24
Adjuvant Chemotherapy for Early Stage Breast Cancer: Current Trends and Future Directions
- 25 February 2010
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 2 (1) , 16-24
Adjuvant Chemotherapy for Early Stage Breast Cancer: Current Trends and Future Directions
- 1 March 2003
- Published by Hindawi Limited in The Breast Journal
- Vol. 9 (2) , 116-119
Central Nervous System Progression During Systemic Response to Trastuzumab, Humanized Anti-HER-2/neu Antibody, Plus Paclitaxel in a Woman with Refractory Metastatic Breast Cancer
Treatment of selected patients with anti‐HER‐2/neu antibodies alone ( 1 ) or in combination with chemotherapy ( 2 ) may be of benefit to patients with refractory breast cancer. Approximately 30% of breast cancers overexpress HER‐2/neu, a member of the epidermal growth factor receptor family. These patients may have a poorer overall prognosis ( 3 ) due to relative resistance to both hormonal therapy and chemotherapy 4-6 ). We recently observed a patient with refractory breast cancer who responded to rhuMAB HER‐2 (trastuzumab) plus paclitaxel after progressing on paclitaxel alone. While on combination treatment she developed cerebellar metastases. Follow‐up computed tomography (CT) scan revealed that her disease continued to respond in the liver, lungs, and bone. This case suggests that failure of trastuzumab to cross the blood–brain barrier may compromise its overall effectiveness and raises the possibility that the central nervous system (CNS), or other sanctuary sites, may become clinically more significant in patients with breast cancer in the era of antibody‐based therapies.
- 1 March 2003
- Published by Hindawi Limited in The Breast Journal
- Vol. 9 (2) , 116-119
Central Nervous System Progression During Systemic Response to Trastuzumab, Humanized Anti-HER-2/neu Antibody, Plus Paclitaxel in a Woman with Refractory Metastatic Breast Cancer
Treatment of selected patients with anti‐HER‐2/neu antibodies alone ( 1 ) or in combination with chemotherapy ( 2 ) may be of benefit to patients with refractory breast cancer. Approximately 30% of breast cancers overexpress HER‐2/neu, a member of the epidermal growth factor receptor family. These patients may have a poorer overall prognosis ( 3 ) due to relative resistance to both hormonal therapy and chemotherapy 4-6 ). We recently observed a patient with refractory breast cancer who responded to rhuMAB HER‐2 (trastuzumab) plus paclitaxel after progressing on paclitaxel alone. While on combination treatment she developed cerebellar metastases. Follow‐up computed tomography (CT) scan revealed that her disease continued to respond in the liver, lungs, and bone. This case suggests that failure of trastuzumab to cross the blood–brain barrier may compromise its overall effectiveness and raises the possibility that the central nervous system (CNS), or other sanctuary sites, may become clinically more significant in patients with breast cancer in the era of antibody‐based therapies.